JT001 (VV116) for the Treatment of COVID-19

Summary

The purpose of this study is to evaluate the efficacy and safety of JT001 (VV116) in participants with mild to moderate COVID-19.

Timeline

Start

2022-10-21

Primary completion

2023-02-14

Completion

2023-02-14

Outcome

Met primary endpoint

paper VV116 significantly reduced the time to sustained clinical symptom resolution compared with placebo, with no observed safety concerns. PMID 38006892 ↗

paper substantial reduction in time to sustained clinical symptom resolution was observed for VV116 compared with placebo among 1296 patients (HR 1·17, 95% CI 1·04-1·33; p=0·0009) PMID 38006892 ↗

Publications

• Fan X, Dai X, Ling Y, Wu L, Tang L, Peng C, Huang C, Liu H, Lu H, Shen X, Zhang W, Wang F, Li G, Li M, Huang Y, Zhang H, Li M, Ren F, Li Y, Liu C, Zhou Z, Sun W, Yi Y, Zhou D, Gao H, Pan Q, Liu H, Zhao J, Ding Z, Ma Y, Li W, Wang Q, Wang X, Bai Y, Jiang X, Ma J, Xie B, Zhang K, Li L. Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study. Lancet Infect Dis. 2024 Feb;24(2):129-139. doi: 10.1016/S1473-3099(23)00577-7. Epub 2023 Nov 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JT001	Small molecule	0.3 g	Oral

Indications

No indication recorded.